I would love to show up at the bank ruptcy hearing and put in my two cents about this stuff. I agree, I have a question how is RP stock showing as indirect ownership did he transfer the rights or is he locked out from trading still.
I have heard time believing there is not some sort of collusion going on. I wonder how Hercules fits into ths schrade, they are a viable business that has to stay in business and one would wonder how this affects their prospects.
I can see taking someone down because of owing money but the ratio covenants are legal but you wonder about the ethics behind that play.
That would be the question I have as well, is this a scam, I would say yes. I have a hard time believing that there is some sort of collusion here. Maybe the end result will tell the story but OCZ has been as misleading as any company I have ever seen. They often say silence is golden unless of course you are cheating and lying all which fit the bill here.
I have always thought it was a scam but I was thinking it was more on the short side and OCZ just continued to play into it with bad decision making by RP but over the last year and what half now sine you and I met I am coming to believe that the real scam is the management running this company. I have always said since RS came on board he did not have the passion to deliever, I was right there and was hoping the products would win out. Its hard to argue the products the awards and stats speak well but the dollars and sense do not.
Thanks for the bantering over the last year and half.
It is not coincidence that Toshy and OCZ released news segements around the same time. Toshiba announced mid year they were refocusing and reorganizing and part of the strategy is to build out in nand of 200 to 300 million investment.
As well OCZ announces expansions into other areas of California.
This week a day before the OCZ news release Toshiba announced that business units are still reorganizing and some units will be pushed back to first quarter or end of first quarter 2014.
The message here people is this will be done by first quarter 2014.
Tekmira and Arrow Research are moving the last few days to months. Tekmira maybe the best long term play in the RNA space. They have leased out their research to Alnylam and they have a lipid product that is looking incredible, think Regeneron type like numbers with the reduction. Tekmira also has some relationships with BMS and others.
Arrow had an incredible data in a hepatitis product that looks ground breaking and is expected to release mid 2014.
The Brooks Brothers do own both of these stock and I am hoping to add some in a fashioned manner. Anyother RNA stocks that have a deep pipeline or nice targets please share.
Who says Hercules cannot waive their rights for more cash inducements, it does not look good to be a loan shark and destroy market preception. I hope Celsion is listening to this.
Wouldn't Hercules send out a notice to OCZ to let them know they are not at the ratios and action is going to be taken or did they act like Uncle Joey and just walk in the door the first chance ?
How long do these type of processes take does the SEC have a time demand on such a process after such news has been made public
Anyother timeline thoughts? I think we all agree how did Toshiba announce a Nand expansion in July and did it make it to this kind of a process, other than manipulation?
Even they said there would be a strategic announcement during the last conference call. How could they either lie or trust Hercules, they new they were going to be behind the ratios. This company is as corrupt as they come or either stupid as they come, I have never seen so many screw ups and lies from a single company. The chinese stock are not this bad.
It is crazy to say the least, it all sounds rigged. Maybe they do not want RP to have anything at all. This whole situation is like something I have never seen, this stuff happens daily with this company on how they cannot tell the truth or stand up before #$%$ happens, that is what manageent is suppose to do not hang out in boats and NY City and do nothing to drive value for the company. What a sick bunch of twits
Will all you idiots quit comparing different mechanism of action and thought processes to outcomes across a class. The future and present is cocktail therapy in cancer, meaning more than one or two possibly a series of events. Once again for 32nd time this week, please review how many new products are being studied for Glio and you will be blown away. This niche market is huge for winner but there will be many new treatments in this disease in 5 more years that offer hope.
I have said this for years its because over 40% of the drugs in research are in cancer is probably one reason. The real reason is pointing toward better targeted cellular treatments that attack the bad cells but also new immunology build up the body. In cancer this approval process makes alot of sense. The problem with drug companies and molecues is for some reason a person can take one product that hit a certain pathway and not respond but take a competing products that hits the same process but responds. These chemical make up are very interesting but for this subject I dare say they are thinking or specific antibody targets, rna processes and other that are starting to dominate the cancer treatement.
It makes you wonder if they liquidate can they choose their own path or will it be useless.
Seems pretty scammy to me, you let revenues fall of the face of the earth, you change warrants and ratios to keep contract in terms, you claim all vendors are paid on time, Toshiba announces a 300 million dollar nand build out. Why is everything this company touches a scam or smell of corruption and never in favor of the shareholders? This company is easily worth 200 to 300 million in a fire sale.
I like Xoma have for years but always gave up on it but the diabetes stuff looks very interesting and they have experience in getting to market. I think its a buy.
My firm advice is play first to market. The patient testimonies on the product are very good and good data but low trial numbers if I remember right. I would not chase glioblastoma stocks other than this one or others with full blown out pipelines. You will not see the return. There are over 30 at my last count stock in Glioblastoma. Do more research and diversify if you already own CLDX now if you are playing for the price jump or momentum then you have to play the news and trial results and there I would target the clinical trials . gov use Pubmed for journal reviews. I see Glio being very crowded in 5 more years but still more a targets approach for instance Avastin, Rindo with a targeted Adenovirus product such as DNatrix or another dendritic cell play such as NWBO or Imuc. I personally think Immunomedics, Mack are good plays because of the antibody profiles and the nice success rate with anibody approvals and they work real good. I would be careful with dendritic cell plays too much. There is so much in cancer I encourage many to look at other disease states.
How do these CFO like Knapp and the dude in there now have jobs? One Knapp must be an RP clone and the duce in there now must be an RS clone. One is saying the company is sound and the other is suppose to have experience in these types of issues. One is a liar and the other is a puppet to RS while ratios in contracts fall and why not discuss another contract amendment on the ratio and other. This sounds like just one big lie.